BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021. [PMID: 34129272 DOI: 10.1111/hepr.13685] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol 2022;22:471. [DOI: 10.1186/s12876-022-02576-4] [Reference Citation Analysis]
2 Drożdż K, Nabrdalik K, Kwiendacz H, Hendel M, Olejarz A, Tomasik A, Bartman W, Nalepa J, Gumprecht J, Lip GYH. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. Cardiovasc Diabetol 2022;21:240. [DOI: 10.1186/s12933-022-01672-9] [Reference Citation Analysis]
3 Perdomo CM, Núñez-córdoba JM, Ezponda A, Mendoza FJ, Ampuero J, Bastarrika G, Frühbeck G, Escalada J. Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease. Front Med 2022;9:1023583. [DOI: 10.3389/fmed.2022.1023583] [Reference Citation Analysis]
4 Seo JY, Cho EJ, Kim MJ, Kwak MS, Yang JI, Chung SJ, Yim JY, Yoon JW, Chung GE. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle 2022. [PMID: 36222309 DOI: 10.1002/jcsm.13099] [Reference Citation Analysis]
5 Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, Hong X, Cheng Y, Wu Q, Zhang X, Feng Z, Wang M. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol 2022;13:934225. [DOI: 10.3389/fendo.2022.934225] [Reference Citation Analysis]
6 Sarin SK, Eslam M, Fan JG, Lin HC, George J, Omata M. MAFLD, patient-centred care, and APASL. Hepatol Int 2022. [PMID: 36070122 DOI: 10.1007/s12072-022-10408-6] [Reference Citation Analysis]
7 Lee H, Lim TS, Kim SU, Kim HC. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol Int 2022. [PMID: 36070124 DOI: 10.1007/s12072-022-10407-7] [Reference Citation Analysis]
8 Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, Anzai K, Kawaguchi T. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr 2022;14:115. [PMID: 35974418 DOI: 10.1186/s13098-022-00887-w] [Reference Citation Analysis]
9 Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens) 2022. [PMID: 35921046 DOI: 10.1007/s42000-022-00391-w] [Reference Citation Analysis]
10 Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George J. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35710982 DOI: 10.1038/s41575-022-00635-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sumida Y. Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. Hepatol Res 2022;52:415-6. [PMID: 35591814 DOI: 10.1111/hepr.13762] [Reference Citation Analysis]
12 Fouad Y, Abdel Salam S, AbdAllah M, Attia D. The change from NAFLD to MAFLD expands fatty liver information flow. Hepatol Res 2022;52:488-9. [PMID: 35591812 DOI: 10.1111/hepr.13752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
14 Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, Kim SU, Lee JI. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Dig Dis Sci 2022. [PMID: 35579799 DOI: 10.1007/s10620-022-07508-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zou Y, Li Q, Gao J, Pan J, Ma J, Chen L, Lin J, Mo Y, Zhang X, Liu P, Dai L. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. Front Cardiovasc Med 2022;9:884636. [DOI: 10.3389/fcvm.2022.884636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Fouad Y, Abdel Dayem WA, Mehrez M. Letter to the editor: Apples should be compared with apples. Hepatology 2022. [PMID: 35532941 DOI: 10.1002/hep.32564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rui F, Yang H, Hu X, Xue Q, Xu Y, Shi J, Li J. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes and Diseases 2022;4:49-55. [DOI: 10.1097/im9.0000000000000089] [Reference Citation Analysis]
18 Vázquez-Medina MU, Cerda-Reyes E, Galeana-Pavón A, López-Luna CE, Ramírez-Portillo PM, Ibañez-Cervantes G, Torres-Vázquez J, Vargas-De-León C. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019. Hepatol Commun 2022. [PMID: 35438253 DOI: 10.1002/hep4.1957] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Chen X, Zhou J, Wu L, Zhu X, Deng H. MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients. Diabetes Metab Syndr Obes 2022;15:673-83. [PMID: 35256849 DOI: 10.2147/DMSO.S351492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90. [PMID: 35248211 DOI: 10.1016/S2468-1253(22)00062-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 31.0] [Reference Citation Analysis]
21 Tsutsumi T, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. Hepatol Res 2022;52:317-9. [PMID: 35229393 DOI: 10.1111/hepr.13738] [Reference Citation Analysis]
22 Grabherr F, Grander C, Effenberger M, Schwärzler J, Tilg H. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us. Therapeutic Advances in Endocrinology 2022;13:204201882211391. [DOI: 10.1177/20420188221139101] [Reference Citation Analysis]
23 Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2021. [PMID: 34953098 DOI: 10.1111/liv.15139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
24 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
25 Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2021. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yoshio S. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease? Hepatol Res 2021;51:1097-9. [PMID: 34724294 DOI: 10.1111/hepr.13717] [Reference Citation Analysis]
27 Tamaki N, Kurosaki M, Higuchi M, Izumi N. Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. Hepatol Res 2021;51:1172-3. [PMID: 34724297 DOI: 10.1111/hepr.13700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A, Higurashi T, Kato S, Hosono K, Saito S, Nakajima A. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol 2021;56:1022-32. [PMID: 34601620 DOI: 10.1007/s00535-021-01828-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
29 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]